Siren Biotechnology, Inc.

@SirenBio is headed to #ASGCT2026 next week! Find us at the events below to learn more about our path to the clinic with #SRN101, our lead AAV immuno #genetherapy for #cancer. See you in Boston! Happy Hour RSVP: luma.com/kl56nvvt

BIG moment for @SirenBio 🚨 We’re thrilled to share that our first peer-reviewed manuscript is now published in @CellPressNews Molecular Therapy Oncology - and we’re heading to @ASGCTherapy 2026 with even more data to share! This publication showcases the foundation of our Universal AAV Immuno-Gene Therapy platform, including groundbreaking preclinical data in high-grade glioma, one of the toughest cancers with the greatest unmet need. Huge thanks to our team and collaborators for supporting this work! 👉 Read the full press release here: sirenbiotechnology.com/siren-biotechn… 👉 Access the open access manuscript here: cell.com/molecular-ther… Want more, like our IND large animal data?! Come find us at #ASGCT2026! #AAV #GeneTherapy #Immunotherapy #Oncology #Publication

Join @SirenBio's CEO @Nicole_Paulk and other industry leaders at the NORD Scientific Symposium next week! We’ll be sharing ways to bring community members in as company stakeholders through community fundraising. Register here: nordscience.org

Thrilled to see @SirenBio SAB member Beverly Davidson recognized with the Outstanding Achievement Award by @ASGCTherapy! A well-deserved honor celebrating her pioneering work and lasting impact on the field 🌟

Big news for SRN-101 🚀 The FDA has cleared a second IND to launch a Phase 1 trial with SRN-101 in recurrent high-grade glioma. This investigator-initiated study, led by Dr. Nicholas Butowski at @UCSF, marks an exciting step forward in expanding clinical evaluation of SRN-101. We’re so proud to support the UCSF team as they advance this important work for patients in need! Learn more: sirenbiotechnology.com/Siren-Biotechn…

On the heels of IND clearance for SRN-101, we are thrilled to announce another major milestone at @SirenBio! 🚀 The FDA has granted #FastTrack Designation to SRN-101, our lead Universal #AAV Immuno-Gene Therapy candidate for recurrent high-grade glioma 🧠 Fast Track status reinforces the urgency and potential impact of bringing this first-of-its-kind therapy to patients. Momentum is building and we’re just getting started! 💥

The @SirenBio team is heading to Phacilitate #ATW26 next week. Our Founder & CEO, @Nicole_Paulk, and our SVP of Vector Development Nathalie Clement look forward to meeting with partners, peers, and fellow leaders pushing the field forward. If you’ll be in San Diego, we’d love to see you!

A big day of celebration here at @SirenBio! 🎉 We’re thrilled to share that the FDA has cleared our first IND for SRN-101, enabling our Phase I/II trial of what we believe is the first #AAV #GeneTherapy for any #cancer clinically. This milestone marks a major step forward in bringing SRN-101 to patients with recurrent high-grade glioma. Huge congratulations to our incredible team, advisors, and partners who helped make this moment possible!

It’s a busy start to 2026 at @SirenBio! We’re excited to be out in full force at #JPM2026, #ATW2026, and #BiocomGPIC. Come meet with us at: 📍 JPM Jan 12-15 | San Francisco, CA 📍 Advanced Therapies Feb 9-12 | San Diego, CA 📍 Biocom Feb 24-26 | La Jolla, CA If you’ll be there too, let’s connect!

@ASGCTherapy We hope folks enjoy this! #GeneTherapy

Dr. Niki Paulk, CEO and Founder of @SirenBio joins the podcast for a timely conversation on turning scientific promise into commercial success. 🎧 Listen now: asgct.org/education-care…

Happy holidays from the @SirenBio team!🎄Our key moments were submitting our first IND to the FDA (today!) and closing our first-ever community investment round. But these can’t overshadow all the other accomplishments our team had in 2025. In all, we counted: ⚡ 8 new cancer indications tested 💸 1,529 new investors ✍️ First IND filed 🧠 3 new SAB members 🧪 10 formal assay qualifications 🏅 3 big awards received 🧬 100+ new constructs screened 💪 1 cancer diagnosis AND recovery! 💼 7 conferences attended 🐣 1 new baby 📆 50 weekly syncs and 26 lab meetings 🥹 1 proud team with ♾️ accomplishments…make that ♾️ + 1! 💛 Stay tuned for our 2026 tally…

🚀 Hey #founders and builders! Thinking about opening your own community investment round? We just dropped the full recording of our webinar where the @SirenBio team walks through how we approached - and successfully ran - our own community round. It’s not legal or financial advice, just an honest look at what worked for us (and what we learned along the way). If you’re a founder curious about bringing your supporters in as investors, this is a great place to start. Featuring: @Nicole_Paulk and Akela Kuwahara from @SirenBio Nina Ekmescic from Capital Department Jonny Price from @Wefunder 🎥 Watch the full video here: youtu.be/kn4gEIIS_sc #StartupFunding #CommunityRound #BiotechStartups #Founders

@FrankJWoods2 $4.2 million 😎

@SirenBio Did you hit 4mil in Community Round?

Final Call: @SirenBio's Community Round Is Closing Soon! 🚨 When we opened this raise, we set out to do something bold – not just in the lab, but in how we build this company. We invited you, our community, to help shape the future of #cancer care. And the response? Absolutely incredible. Since launching this round, we’ve hit major milestones: 💸 $3M+ raised 👥 1,250+ investors have joined the mission 🏆 Named Start-Up of the Year at Advanced Therapies Week 🎤 Took the stage at SXSW to spotlight our universal gene therapy 🎖️ First patent granted protecting core tech behind SRN-101 🐖 Large-animal studies launched to advance toward human trials 🧬 Successful Pre-IND meeting with the FDA, keeping us on track for the clinic in 2026 👩‍🔬 GMP production of SRN-101 is officially underway Our community round is closing in *just a few weeks*. If you’ve been thinking about investing (or upping your stake), now is your chance. Invest or increase your investment today: lnkd.in/gNdrgNck Here’s to a strong close!! 🚀

Curious what it was like to launch one of the first ever biotech community investment rounds? We're hosting a webinar for founders and builders next week! RSVP here: luma.com/w1j7jtrv

Wow — what a way to close out our first-ever community round! 🎉 We’re incredibly grateful to the 1,600+ investors who joined our mission and helped us raise over $4.2 million to support the next generation of cancer gene therapy. This round wasn’t just about funding. It was about opening the doors to patients, families, advocates, doctors and anyone who believes cancer care has to be faster, smarter, and more effective. We’re honored to have you with us on this journey. 📝Check out our final campaign update on Wefunder: wefunder.com/siren.biotechn… Here’s to an exciting chapter ahead!

Only a few hours left, and that’s it! ⏳ The momentum in these final hours has been incredible. We’re closing in on $4M raised from over 1,500 investors, and we couldn’t be more proud of what this community has built. Here’s why investors are excited about Siren: 🧬Universal AAV gene therapy for cancer 💸$28M raised from top-tier VCs including Founders Fund and Lux Capital 🏆Named 2025 Start-Up of the Year at Phacilitate Advanced Therapies Week 🔬550+ animals treated with curative preclinical data 🧪Clinical trials targeted for 2026 🎓Team from Stanford, UCSF, Duke, Mount Sinai, and Roche 🎖️First patent family awarded 👑Called “perhaps the most de-risked pharma startup” by Kingscrowd 🌍Tackling a $3.2B+ global market for brain tumor therapeutics 🎙️Featured at SXSW 2025 We opened this round to give more people a seat at the table in building the future of cancer care and we’ve been blown away by your belief, support, and boldness. ❤️ 🚨Join us or increase your stake before our round closes for good → wefunder.com/sirenbiotechno…

@woodien @harmonybabyfood Woot woot 🎉 Wefunder.com/siren.biotechn…

The line between VC and the crowd is officially blurring. Today's Crowd Favorites report features companies backed by top-tier funds. Big congrats to @harmonybabyfood and great to see @SirenBio back on the list before their round closes.

🚨We’re almost at the finish line – Siren’s community investment round closes TONIGHT This is your final chance to invest in the company developing a universal AAV immuno-gene therapy for cancer. 💸 $28M raised from top VCs including Founders Fund, Lux Capital & more 🧬 $3.8M+ raised from 1,500+ community investors (and counting!) 🏆 2025 Start-Up of the Year at Phacilitate Advanced Therapies Week 🧠 Game-changing universal AAV gene therapy 🔬 550+ animals treated with curative preclinical data 🧪 Targeting clinical trials in 2026, a critical step toward FDA approval 🎓 Powerhouse team from Stanford, UCSF, Duke, Mount Sinai, and Roche 🌍 $3.2B global market for brain tumor therapeutics Let’s bring a radically new kind of cancer treatment into the world. 🎯Invest or increase your investment before 11:59pm EST: 👉wefunder.com/sirenbiotechno… Here we go!

We just wrapped our Virtual Closing Celebration and we’re still feeling the energy and deep gratitude from this incredible community. 🥂 1,450+ #investors have already joined our mission to change the future of #cancer care and we can’t keep count fast enough! If you missed the event, the replay is now live: 🎥Watch the replay → youtube.com/watch?v=QWJUEq… 📅Book a call with our Founder & CEO → calendly.com/npaulk/15-min-… Our community round closes in just a few days, and we don’t plan to open another. If you’ve been thinking about investing, increasing your stake, or sharing this with someone who should be part of it, act now. This has been one of the most meaningful chapters in Siren Biotechnology's journey. Let’s finish strong! 🚀 🔗 Invest now at wefunder.com/sirenbiotechno….

Join the @SirenBio team for our final community investor webinar TODAY! 🗓 Wednesday, October 15 🕚 11:30am PT / 2:30pm ET 🎟️ RSVP here: luma.com/dlyq5t6j Can't make the webinar but still want to chat about investing before the round closes this week? Book a time to speak with our Founder and CEO, @Nicole_Paulk here! calendly.com/npaulk/15-min-…